Literature DB >> 23075762

Routine use of clinical management guidelines in Australian general practice.

Mark F Harris1, Jane Lloyd1, Yordanka Krastev1, Mahnaz Fanaian1, Gawaine Powell Davies1, Nick Zwar2, Siaw-Teng Liaw2.   

Abstract

Significant gaps remain between recommendations of evidence-based guidelines and primary health care practice in Australia. This paper aims to evaluate factors associated with the use of guidelines reported by Australian GPs. Secondary analysis was performed on a survey of primary care practitioners which was conducted by the Commonwealth Fund in 2009: 1016 general practitioners responded in Australia (response rate 52%). Two-thirds of Australian GPs reported that they routinely used evidence-based treatment guidelines for the management of four conditions: diabetes, depression, asthma or chronic obstructive pulmonary disease and hypertension - a higher proportion than in most other countries. Having non-medical staff educating patients about self-management, and a system of GP reminders to provide patients with test results or guideline-based intervention or screening tests, were associated with a higher probability of guidelines use. Older GP age was associated with lower probability of guideline usage. The negative association with age of the doctor may reflect a tendency to rely on experience rather than evidence-based guidelines. The association with greater use of reminders and self-management is consistent with the chronic illness model.

Entities:  

Mesh:

Year:  2014        PMID: 23075762     DOI: 10.1071/PY12078

Source DB:  PubMed          Journal:  Aust J Prim Health        ISSN: 1448-7527            Impact factor:   1.307


  7 in total

1.  Improving chlamydia knowledge should lead to increased chlamydia testing among Australian general practitioners: a cross-sectional study of chlamydia testing uptake in general practice.

Authors:  Anna Yeung; Meredith Temple-Smith; Simone Spark; Rebecca Guy; Christopher K Fairley; Matthew Law; Anna Wood; Kirsty Smith; Basil Donovan; John Kaldor; Jane Gunn; Marie Pirotta; Rob Carter; Jane Hocking
Journal:  BMC Infect Dis       Date:  2014-11-07       Impact factor: 3.090

2.  Overview of preventive practices provided by primary care physicians: A cross-sectional study in Switzerland and France.

Authors:  Paul Sebo; Hubert Maisonneuve; Bernard Cerutti; Jean-Pascal Fournier; Nicolas Senn; Cédric Rat; Dagmar M Haller
Journal:  PLoS One       Date:  2017-09-05       Impact factor: 3.240

3.  Management of fever in Australian children: a population-based sample survey.

Authors:  Joanna Holt; Leslie White; Gavin R Wheaton; Helena Williams; Shefali Jani; Gaston Arnolda; Hsuen P Ting; Peter D Hibbert; Jeffrey Braithwaite
Journal:  BMC Pediatr       Date:  2020-01-13       Impact factor: 2.125

4.  Physicians' views on the usefulness of practical tools for assessing the driving ability of older drivers: a cross-sectional study.

Authors:  Paul Sebo
Journal:  Fam Med Community Health       Date:  2020-08

5.  Preventive evidence into practice (PEP) study: implementation of guidelines to prevent primary vascular disease in general practice protocol for a cluster randomised controlled trial.

Authors:  Mark F Harris; Jane Lloyd; John Litt; Mieke van Driel; Danielle Mazza; Grant Russell; Jane Smith; Chris Del Mar; Elizabeth Denney-Wilson; Sharon Parker; Yordanka Krastev; Upali W Jayasinghe; Richard Taylor; Nick Zwar; Jinty Wilson; Helen Bolger-Harris; Justine Waters
Journal:  Implement Sci       Date:  2013-01-18       Impact factor: 7.327

6.  Preparing pharmacists to deliver a targeted service in hypertension management: evaluation of an interprofessional training program.

Authors:  Beata V Bajorek; Kate S Lemay; Parker J Magin; Christopher Roberts; Ines Krass; Carol L Armour
Journal:  BMC Med Educ       Date:  2015-09-28       Impact factor: 2.463

Review 7.  Rational oral corticosteroid use in adult severe asthma: A narrative review.

Authors:  Li Ping Chung; John W Upham; Philip G Bardin; Mark Hew
Journal:  Respirology       Date:  2019-11-12       Impact factor: 6.424

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.